Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jun 1;4(6):995-1004.
doi: 10.1039/C7QO00052A. Epub 2017 Feb 9.

Synthesis and Structure Revision of Symplocin A

Lu-Ping Shao  1 , Chang-Mei Si  1 , Zhuo-Ya Mao  1 , Wen Zhou  1 , Tadeusz F Molinski  2 , Bang-Guo Wei  1 , Guo-Qiang Lin  1
Affiliations

Synthesis and Structure Revision of Symplocin A

Lu-Ping Shao et al. Org Chem Front. .

Abstract

Symplocin A, a linear peptide possessing N-terminal N,N-dimethylisoleucine, statine, and valic acid residues, has been synthesized for the first time employing our previously established 'one-pot intramolecular tandem protocol'. Moreover, the stereochemistry of natural symplocin A was unambiguously revised through the confirmation by 1D NMR, 2D NMR, and HPLC comparisons with authentic natural product.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
The Structures of DMAA Linear Peptides.
Figure 2.
Figure 2.
Retrosynthetic analysis of 3a.
Scheme 1.
Scheme 1.
Preparation of Tetrapeptide Fragment 8. Reagents and conditions: (a) NaH, MeI, THF; (b) L-Pro-OMe, HATU, DIPEA, DCM, 62% (2 steps); (c) (1) TFA, DCM; (2) Boc-Gly, HATU, DIPEA, DCM, 80% (2 steps); (d) (1) TFA, DCM; (2) Boc-Val-OH, HOBt, EDCI, DMF, 62% (2 steps).
Scheme 2.
Scheme 2.
Preparation of (3R,4S)-Statine Subunit 7. Reagents and conditions: (a) TBAF, THF, 50%; (b) LiOH•H2O, H2O2, THF/H2O, 100%.
Scheme 3.
Scheme 3.
Preparation of Depsipeptide Fragment 19. Reagents and conditions: (a) DCC, DMAP, DCM, 76%; (b) (1) TFA, DCM; (2) HCHO, NaBH3(CN), CH3CN, 64% (2 steps); (c) (1) Pd(PPh3)4, N-methylaniline, NMA, THF; (2) 5, HATU, HOAt, DIPEA, DCM, 45% (2 steps); (d) H2, 1 atm, Pd/C, MeOH, 100%.
Scheme 4.
Scheme 4.
Preparation of Symplocin A (3a). Reagents and conditions: (a) (1) TFA, DCM; (2) 7, HATU, HOAt, DIPEA, DMF, 59% (2 steps); (b) (1) TFA, DCM; (2) 6, HOBt, EDCI, NMM, DMF, 70% (2 steps); (c) (1) TFA, DCM; (2) 19, HOBt, EDCI, NMM, DCM, 38% (2 steps).
Scheme 5.
Scheme 5.
Preparation of (50S, 51S)-Symplocin A (3b). Reagents and conditions: (a) (1) 16, DCC, DMAP, DCM; (2) TFA, DCM; (3) HCHO, NaBH3(CN), CH3CN, 37% (3 steps); (b) (1) Pd(PPh3)4, N-methylaniline, NMA, THF; (2) 5, HATU, HOAt, DIPEA, DCM, 31% (2 steps); (c) (1) H2, 1 atm, Pd/C; (2) free amine of 21, HOBt, EDCI, NMM, DCM, 26% (2 steps).
Scheme 6.
Scheme 6.
Preparation of (26S, 50S, 51S)-Symplocin A (3c). Reagents and conditions: (a) (1) (COCl)2, DMSO, DCM; (2) NaBH4, MeOH, 67% (2 steps); (b) LiOH•H2O, H2O2, THF/H2O, 100%; (c) free amine of 8, HATU, HOAt, DIPEA, DMF, 87%; (d) (1) TFA,DCM; (2) 6, HOBt, EDCI, NMM, DMF, 37% (2 steps); (3) TFA,DCM; (4) (2S,3S)-19, HOBt, EDCI, NMM, DCM, 21% (2 steps).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Hamada Y and Shioiri T, Chem. Rev. (Washington, DC, U. S.), 2005, 105, 4441; - PubMed
    2. Bionda N and Cudic P, Croat. Chem. Acta, 2011, 84, 315;
    3. Salvador-Reyes LA and Luesch H, Nat. Prod. Rep, 2015, 32, 478; - PMC - PubMed
    4. Vijayakumar S, Manogar P and Prabhu S, Biomed. Pharmacother, 2016, 83, 362. - PubMed
    1. Simmons TL, McPhail KL, Ortega-Barria E, Mooberry SL and Gerwick WH, Tetrahedron Lett, 2006, 47, 3387;
    2. Maderna A and Leverett CA, Mol. Pharmaceutics, 2015, 12, 1798; - PubMed
    3. Gunasekera SP, Imperial L, Garst C, Ratnayake R, Dang LH, Paul VJ and Luesch H, J. Nat. Prod, 2016, 79, 1867. - PMC - PubMed
    1. Luesch H, Moore RE, Paul VJ, Mooberry SL and Corbett TH, J. Nat. Prod, 2001, 64, 907. - PubMed
    1. Gerber H-P, Koehn FE, Abraham RT, Nat. Prod. Rep, 2013, 30, 625; - PubMed
    2. Perez EA, Hillman DW, Fishkin PA, Krook JE, Tan WW, Kuriakose PA, Alberts SR and Dakhil SR, Investigational New Drugs, 2005, 23, 257; - PubMed
    3. Kindler HL, Tothy PK, Wolff R, McCormack RA, Abbruzzese JL, Mani S, Wade-Oliver KT and Vokes EE, Investigational New Drugs, 2005, 23, 489. - PubMed
    1. Kwan JC, Eksioglu EA, Liu C, Paul VJ and Luesch H, J Med Chem, 2009, 52, 5732. - PMC - PubMed